North America Microvillus Inclusion Disease Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

North America Microvillus Inclusion Disease Market Size

• The North America microvillus inclusion disease market size was valued at USD 793.20 million by 2033 from USD 575.70 million in 2025, growing at a CAGR of 4.1% during the forecast period. The North America microvillus inclusion disease market is experiencing steady growth, driven by the increasing prevalence of rare congenital intestinal disorders, rising awareness regarding early diagnosis, and the growing demand for advanced nutritional support therapies, parenteral nutrition solutions, and specialized paediatric care.

Increasing investments in rare disease research, advancements in genetic testing technologies, and expanding healthcare infrastructure across developed and emerging economies are significantly supporting market growth, along with the rising focus on improving long-term disease management and patient survival outcomes worldwide.

Market Size & Forecast

• Market Value (2025): USD 575.70 million
• Expected Market Value (2033): USD 793.20 million
• Forecast CAGR (2026–2033): 4.1%
• Leading Country in 2025: U.S.
• Fastest Growing Country: Mexico

Key Market Trends & Insights

• U.S. dominated the North America microvillus inclusion disease market primarily with a market share of 78.40% in 2025, due to its advanced healthcare infrastructure, strong capabilities in genetic diagnostics, increasing focus on rare disease management, and high adoption of specialized pediatric treatment approaches.
• The Mexico is expected to be the fastest-growing country in the North America Microvillus Inclusion Disease (MVID) Market with a CAGR of 4.3% due to the expanding healthcare sector, growing awareness of rare genetic disorders, increasing access to molecular diagnostic technologies, and rising investments in pediatric healthcare services.
• In 2026, the Early-Onset (Congenital) MVID segment is expected to dominate the market with a market share of 33.20%, due to the fact that most diagnosed cases manifest during infancy, requiring early diagnosis, intensive nutritional management, and long-term clinical care.
• Intravenous (IV) accounts for 61.90% of the market, due to severe intestinal malabsorption and inability to absorb nutrients orally. The dominance of IV administration is further supported by its ability to ensure precise nutrient delivery, maintain fluid and electrolyte balance, and support growth and survival in pediatric patients. Increasing use of home-based IV nutrition programs, advancements in catheter technology, and improved infection management protocols are also contributing to its widespread adoption.
• The subcutaneous segment is the fastest-growing category, with a CAGR of 4.5%, driven by increasing adoption of less invasive and more patient-friendly delivery methods for supportive therapies in rare disease management, improvements in drug formulation technologies that enable subcutaneous absorption of specialized nutrients and biologics, and growing interest in home-based care models that reduce hospital dependency.

North America Report Scope and Microvillus Inclusion Disease Market Segmentation

Trend: Advancements in Genetic Diagnostics and Personalized Treatment Approaches

The global microvillus inclusion disease (MVID) market is witnessing significant advancements driven by the integration of sophisticated genetic diagnostic technologies and personalised treatment strategies. Whole exome sequencing (WES), next-generation sequencing (NGS), and molecular diagnostic platforms are increasingly being adopted to identify MYO5B gene mutations responsible for MVID, enabling earlier diagnosis, improved diagnostic accuracy, and timely clinical intervention in infants and paediatric patients. Early genetic confirmation is facilitating better disease management while reducing diagnostic delays commonly associated with rare congenital disorders.

In parallel, personalised treatment approaches, including customised parenteral nutrition regimens, precision medicine strategies, targeted supportive therapies, and multidisciplinary care models, are improving patient outcomes and quality of life. Advances in intestinal rehabilitation programmes, enhanced parenteral nutrition formulations, specialised paediatric monitoring systems, and digital integration of electronic health records (EHRs), rare disease registries, and genetic research databases are supporting data-driven clinical decision-making, standardised patient management, and accelerated research activities. These developments are collectively transforming the clinical management landscape and driving innovation in the global MVID market.

Key Market Driver: Advancements in Genetic Diagnostics and Next-Generation Sequencing

Advancements in genetic diagnostics and next-generation sequencing (NGS) technologies are a primary driver of the global microvillus inclusion disease market. These technologies enable accurate identification of disease-causing mutations, particularly in the MYO5B gene, allowing clinicians to diagnose MVID at an early stage and initiate timely clinical interventions. Improved diagnostic accuracy supports better patient management, genetic counselling, and the development of personalised therapeutic strategies while reducing the likelihood of misdiagnosis in this ultra-rare disorder. As healthcare systems continue to adopt advanced genomic technologies and precision medicine approaches, the demand for specialised diagnostic services and targeted treatment solutions is expected to increase.

In 2023, according to an article published by Elsevier Inc., researchers developed a novel Myo5b(G519R) mouse model using one-step two-cell embryo microinjection and Cre/loxP technology. This model accurately replicates patient-specific MYO5B mutations, providing valuable insights into disease mechanisms and supporting the development of targeted therapies, thereby contributing to the growth of the global MVID market.

Key Market Restraint/Challenge: Extremely Low Disease Prevalence

The extremely low prevalence of microvillus inclusion disease remains one of the most significant challenges limiting market growth. As an ultra-rare inherited disorder, MVID affects a very small patient population globally, reducing the commercial viability of developing novel diagnostic tools and therapeutic products. The limited number of patients also creates substantial challenges in conducting clinical trials, recruiting eligible participants, and generating robust clinical evidence required for regulatory approvals. Furthermore, limited epidemiological data, low disease awareness, and the absence of standardised treatment guidelines hinder widespread adoption of advanced therapies. These factors collectively restrict research investments, delay product development, and constrain overall market expansion.

In April 2026, according to an article published by BioSpace, ongoing clinical development programmes for MVID continue to explore therapies aimed at reducing dependence on parenteral nutrition while pursuing expedited regulatory pathways, including Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). However, the limited patient population remains a major barrier to large-scale clinical development, funding, and commercialisation, thereby restraining market growth.

Key Market Opportunity: Emergence of Gene Therapy Targeting MYO5B Mutations

The emergence of gene therapy targeting MYO5B mutations represents a significant opportunity for the global microvillus inclusion disease market. Since mutations in the MYO5B gene are the primary cause of MVID, advances in gene editing technologies, viral vector platforms, and precision medicine are creating the potential to treat the disease at its genetic source rather than relying solely on supportive care. Ongoing research into gene replacement and gene correction therapies has the potential to reduce long-term dependence on parenteral nutrition, improve intestinal function, and decrease the need for intestinal transplantation.

Growing investments in rare disease research, favourable orphan drug incentives, increasing collaborations between biotechnology companies and academic institutions, and advancements in genomic medicine are accelerating the development of innovative therapeutic candidates. As more gene therapy programmes progress through preclinical and clinical development, they are expected to expand treatment options and create substantial long-term growth opportunities for the MVID market.

In March 2025, according to BioSpace, Entero Therapeutics, Inc. received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical development pathway for its investigational therapy for microvillus inclusion disease. Alongside continued progress in gene therapy research targeting MYO5B mutations, these developments are expected to strengthen the future treatment landscape and create significant opportunities for market growth.

North America Microvillus Inclusion Disease Market Scope

North America microvillus inclusion disease market is categorized into seven notable segments which are based on disease type / clinical presentation, treatment type, route of administration, diagnosis type, end user, patient demographics, and distribution channel.

• By Disease Type

On the basis of disease type / clinical presentation, the North America microvillus inclusion disease market is segmented into early-onset (congenital) MVID, genetic subtypes, non-syndromic MVID, syndromic mvid, late-onset / atypical MVID. In 2026, the Early-Onset (Congenital) MVID segment is expected to dominate the market with 33.36% market share due to the high prevalence of severe neonatal presentations requiring immediate and long-term medical intervention. Most diagnosed cases occur within the first days or months of life, leading to early dependence on total parenteral nutrition, intensive hospitalization, and specialized pediatric care. Increasing awareness among neonatologists, improvements in genetic diagnostics, and rising adoption of advanced supportive therapies are further contributing to the dominance of this segment in the North America market.

The syndromic MVID segment is expected to be fastest growing with a CAGR of 4.5%, due to increasing recognition of complex genetic syndromes associated with MVID, advancements in molecular diagnostic techniques, and improved identification of patients presenting with extraintestinal manifestations. Growing research into rare genetic disorders, enhanced access to genetic screening programs, and the need for comprehensive multidisciplinary care approaches are further contributing to the growth of this segment. .

• By Treatment Type

On the basis of treatment type, the North America microvillus inclusion disease market is segmented into nutritional support, surgical & advanced interventions, pharmacological management, and emerging & pipeline therapies. in 2026, the nutritional support segment is expected to dominate the market with 68.76% market share due to the critical dependence of microvillus inclusion disease patients on long-term nutritional management for survival. Since the disease severely impairs intestinal absorption, most patients require continuous total parenteral nutrition (TPN) and specialized nutritional formulations from infancy. The absence of widely approved curative therapies, increasing use of home-based TPN systems, and growing focus on improving pediatric nutritional outcomes are further driving demand for nutritional support therapies. Additionally, advancements in customized nutrient formulations and supportive care infrastructure continue to strengthen segment dominance in North America.

The emerging & pipeline therapies segment is expected to be fastest growing with a CAGR of 3.8%, due to increasing investments in rare disease research, ongoing development of gene-based and targeted therapies, and growing efforts to address the underlying genetic causes of MVID. Advancements in precision medicine, expanding clinical research activities, and the demand for more effective long-term treatment options beyond supportive nutritional care are further driving the growth of this segment.

• Route of Administration

 On the basis of route of administration, the North America microvillus inclusion disease market is segmented into intravenous (IV), oral, subcutaneous, enteral, and others. In 2026, the subcutaneous segment is expected to dominate the market with 61.97% market share due to the increasing use of subcutaneous anti-secretory and supportive therapies that provide improved convenience, reduced hospitalization requirements, and enhanced long-term disease management. Several medications used in Microvillus Inclusion Disease management, including octreotide-based therapies, are commonly administered through the subcutaneous route for better patient compliance and sustained therapeutic effects. Growing preference for home-based care, reduced risk of intravenous complications, and advancements in self-administration delivery systems are further supporting the dominance of the subcutaneous segment in the North America market.

The subcutaneous is expected to be fastest growing segment with a CAGR of 4.4%, due to the increasing development of biologic and targeted therapies designed for convenient administration and improved patient compliance. The subcutaneous route offers advantages such as reduced hospital visits, ease of self-administration, and enhanced treatment accessibility, making it an attractive option for long-term management of rare genetic disorders, including emerging therapeutic approaches for MVID.

•  By Diagnosis Type

On the basis of diagnosis type, North America microvillus inclusion disease market is segmented into genetic testing, definitive diagnostics, laboratory testing, and imaging & support diagnostics. In 2026, the genetic testing segment is expected to dominate the market with 39.04% market share due to the growing adoption of advanced molecular diagnostic technologies for early and accurate disease identification. Increasing awareness regarding MYO5B and other associated genetic mutations has accelerated the use of postnatal and prenatal genetic screening in high-risk populations. Genetic testing enables faster confirmation of diagnosis compared to invasive procedures, supporting timely clinical intervention and personalized treatment planning. Additionally, expanding availability of next-generation sequencing technologies and rising demand for carrier screening are further strengthening the dominance of this segment.

The genetic testing is expected to register the highest CAGR of 3.9% in the forecast period. As genetic testing enables faster confirmation of diagnosis compared to invasive procedures, supporting timely clinical intervention and personalized treatment planning. Additionally, expanding availability of next-generation sequencing technologies and rising demand for carrier screening are further strengthening the dominance of this segment.

• By End User

 On the basis of End User, North America microvillus inclusion disease market is segmented into hospitals, pediatric specialty clinics, home healthcare settings (TPN administration), transplant centers, research institutes & academic centers, and others. In 2026, the Hospitals segment is expected to dominate the market with 38.33% market share due to the need for intensive multidisciplinary care and continuous clinical monitoring in patients with severe gastrointestinal complications. Most Microvillus Inclusion Disease patients require prolonged hospitalization for total parenteral nutrition administration, electrolyte management, infection control, and neonatal intensive care support. Hospitals also provide access to advanced diagnostic technologies, pediatric gastroenterologists, transplant services, and emergency interventions essential for disease management. Additionally, increasing availability of specialized pediatric care units and improved hospital-based nutritional support infrastructure are further contributing to segment dominance.

The home healthcare settings (TPN Administration) segment is expected to be fastest growing with a CAGR of 4.4%, due to the increasing preference for home-based long-term care, advancements in Total Parenteral Nutrition (TPN) delivery systems, and the need to reduce prolonged hospital stays. Improved patient monitoring technologies, enhanced caregiver support programs, and growing efforts to improve quality of life for patients with chronic intestinal failure are further driving the adoption of home healthcare settings.

• By Patient Demographics

On the basis of patient demographics, North America microvillus inclusion disease market is segmented into neonates, infants, and pediatric (long-term survivors).  In 2026, the NEONATES segment is expected to dominate the market with 52.83% market share due to the predominantly congenital nature of the disease, with symptoms typically appearing within the first days of life. Severe neonatal diarrhea, dehydration, malabsorption, and rapid nutritional deterioration often require immediate hospitalization and intensive supportive care. Early diagnosis in neonatal intensive care units, increasing use of genetic testing, and dependence on long-term total parenteral nutrition contribute significantly to healthcare utilization in this population. Additionally, rising awareness among pediatric specialists is supporting earlier detection and management of neonatal cases.

The pediatric (long-term survivors) segment is expected to be fastest growing with a CAGR of 4.4%, due to improvements in early diagnosis, advanced nutritional support therapies, and better long-term disease management strategies that have increased survival rates among affected children. Growing access to specialized pediatric care, multidisciplinary treatment approaches, and ongoing monitoring of nutritional and developmental outcomes are further contributing to the expansion of this segment.

• By Distribution Channel

On the basis of distribution channel, the North America microvillus inclusion disease market is segmented into hospital pharmacies, specialty pharmacies, direct procurement, online pharmacies, and others.  In 2026, the hospital pharmacy segment is expected to dominate the Microvillus Inclusion Disease Market with 42.62% market share due to the high dependence on hospital-based treatment and specialized medication management for critically ill patients. Most therapies used in Microvillus Inclusion Disease, including total parenteral nutrition components, electrolyte replacements, antibiotics, and anti-secretory agents, are administered and monitored within hospital settings. Hospital pharmacies ensure immediate access to complex formulations, sterile nutritional preparations, and emergency supportive medications required for neonatal and pediatric care. Additionally, the growing number of specialized pediatric hospitals and multidisciplinary treatment centers is further strengthening the dominance of this segment.

The online pharmacies segment is expected to be fastest growing with a CAGR of 4.4%, due to due to the increasing adoption of digital healthcare platforms, growing demand for convenient access to specialized nutritional products and medications, and expanding e-commerce penetration in healthcare. Enhanced home delivery services, improved availability of prescription management tools, and the rising preference for remote healthcare support among patients and caregivers are further driving the growth of this segment.

Microvillus inclusion disease market Regional Analysis.

The U.S. dominated the microvillus inclusion disease market is driven by its advanced healthcare infrastructure, strong focus on rare disease research, and widespread adoption of precision medicine and genetic testing technologies. Increasing awareness among healthcare professionals, favorable government support for rare disease diagnosis and treatment, and the presence of leading pediatric healthcare institutions are contributing to improved identification and management of microvillus inclusion disease.

Mexico Microvillus inclusion disease market Insight

Mexico is the fastest-growing region in the North America microvillus inclusion disease market, projected to register a CAGR of 4.3% during the forecast period. Rapid improvements in healthcare infrastructure, increasing healthcare expenditure, and rising awareness regarding rare genetic diseases are driving regional market growth. Expanding access to genetic screening programs, improving neonatal healthcare facilities, and rising government initiatives focused on rare disease management are further accelerating demand for effective diagnosis and supportive treatment solutions across the region.

Canada Microvillus inclusion disease market Insight

Canada holds the second-largest share in the North America microvillus inclusion disease market, contributing around 14.60% in 2025. The region benefits from well-established healthcare systems, increasing government support for rare disease management, and rising awareness regarding early diagnosis of congenital intestinal disorders. Growing research activities in precision medicine and genetic diagnostics are supporting improved disease identification and patient management. Furthermore, the presence of specialized pediatric treatment centers and expanding collaboration between research institutes and healthcare providers are enhancing treatment accessibility and improving survival outcomes for patients affected by microvillus inclusion disease across the region.

North America Microvillus Inclusion Disease Market Share

The  microvillus inclusion disease industry is primarily led by well-established companies, including:

• Baxter International Inc. (U.S.)
• Fresenius SE & Co. KGaA (Germany)
• B. Braun SE (Germany)
• Nestlé Health Science (Switzerland)
• Nutricia (Danone Group) (Netherlands)
• Ipsen Pharma (France)
• Gedeon Richter Plc. (Hungary)
• Abbott Laboratories (U.S.)
• Novartis AG (Switzerland)
• Chiesi Farmaceutici S.p.A. (Italy)
• Laboratoire Aguettant (France)
• Sichuan Kelun Pharmaceutical Co., Ltd. (China)
• Kate Farms (U.S.)
• Hexagon Nutrition Ltd. (India)
• Pfizer Inc. (U.S.)
• Jaguar Health (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Luoxin Pharmaceuticals Group Stock Co., Ltd. (China)
• Ajinomoto Cambrooke, Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Phebra Pty Ltd (Australia)
• Nutrisens Medical Italia (Italy)
• Otsuka Pharmaceutical India Private Limited (Japan)
• Aculife Healthcare Pvt. Ltd. (India)
• Functional Formularies (U.S.)
• Kenvue (U.S.)
• Novus Lifesciences Pvt. Ltd. (India)
• USV Private Limited (India)
• Pentagon Labs Ltd. (India)
• Oscar Remedies Private Limited (India)
• Pristine Organics (India)
• Emyris (India)

Latest Developments in North America Microvillus Inclusion Disease Market

• In April 2026, Baxter International showcased its latest innovations in surgical care at the AORN Global Surgical Conference & Expo 2026 in New Orleans, highlighting additions to its surgical solutions and patient support portfolio. The company featured new technologies including the AAT XR spine surgical table and the Dynamo Series smart stretcher aimed at improving operating room efficiency and patient handling. These advancements are expected to strengthen Baxter’s market position by enhancing surgical workflow efficiency, improving patient safety outcomes, and supporting broader adoption of its advanced perioperative solutions.
• In October 2024, B. Braun Medical Inc. announced plans to increase IV fluid production by 20% at its U.S. facilities to address nationwide shortages and strengthen hospital supply continuity for infusion therapy and nutrition support products. This expansion supports healthcare providers by improving availability of critical IV and clinical nutrition supplies during high-demand periods. It will benefit B. Braun by strengthening its position in the hospital infusion and nutrition market, increasing product availability, and building long-term trust with healthcare providers.
• In February 2026, Nestlé Health Science announced the inclusion of its nutritional products under an exceptional reimbursement framework within Portugal’s public health system, allowing eligible products to be partially or fully covered by the National Health Service. This regulatory decision strengthens patient access to clinical nutrition solutions and supports integration of medical nutrition into formal healthcare reimbursement pathways. This will benefit the company by improving product accessibility, expanding prescription-based demand, and reinforcing its position within the reimbursed clinical nutrition market
• In May 2024, Danone is investing €70 million in France to expand its Steenvoorde plant for Nutricia oral nutritional supplements. The project boosts capacity for patients with disease-related malnutrition and includes sustainability upgrades like a biomass boiler to reduce emissions and improve efficiency. This investment will strengthen Danone’s medical nutrition capacity, supporting long-term growth in a high-demand healthcare nutrition segment.
• In 2025, Abbott expanded it Glucerna nutrition product lines in 2025, introducing improved formulations with enhanced protein content, better taste, and additional product formats such as ready-to-drink shakes and snack-based nutrition options. The expansion is aimed at supporting muscle health, diabetes management, aging populations, and clinical nutrition needs in hospital and home-care settings

SKU-76526